Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001562180-20-005109)

Filing Details

Accession Number:
0001562180-20-005109
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-13 16:02:56
Reporting Period:
2020-07-09
Accepted Time:
2020-07-13 16:02:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
842023 Bio-Techne Corp TECH Biological Products, (No Disgnostic Substances) (2836) 411427402
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1443851 S. Brenda Furlow 614 Mckinley Place Ne
Minneapolis MN 55413		 Svp - General Counsel No No No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-07-09 9,079 $108.49 13,390 No 4 M Direct
Common Stock Disposition 2020-07-09 440 $270.97 12,950 No 4 S Direct
Common Stock Disposition 2020-07-09 505 $272.48 12,445 No 4 S Direct
Common Stock Disposition 2020-07-09 2,042 $273.33 10,403 No 4 S Direct
Common Stock Disposition 2020-07-09 918 $274.80 9,485 No 4 S Direct
Common Stock Disposition 2020-07-09 400 $276.03 9,085 No 4 S Direct
Common Stock Disposition 2020-07-09 1,954 $277.28 7,131 No 4 S Direct
Common Stock Disposition 2020-07-09 2,746 $278.06 4,385 No 4 S Direct
Common Stock Disposition 2020-07-09 74 $278.84 4,311 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-07-09 9,079 $0.00 9,079 $108.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
921 2022-08-07 No 4 M Direct
Reported Derivative Holdings
Show Other Fields >>
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Restricted Stock Units $0.00 1,724 1,724 Direct
Common Stock Restricted Stock Units $0.00 1,969 1,969 Direct
Common Stock Restricted Stock Units $0.00 1,374 1,374 Direct
Common Stock Stock Option (Right to Buy) $106.59 2023-08-18 10,857 10,857 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 13,290 13,290 Direct
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 9,786 9,786 Direct
Common Stock Stock Options (Right to buy) $177.32 2025-08-08 7,339 7,339 Direct
Common Stock Stock Options (Right to Buy) $125.05 2024-08-09 12,670 12,670 Direct
Common Stock Stock Options (Right to buy) $125.05 2024-08-09 9,503 9,503 Direct
Common Stock Stock Options (Right to Buy) $106.59 2023-08-18 14,476 14,476 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
1,724 1,724 Direct
1,969 1,969 Direct
1,374 1,374 Direct
2023-08-18 10,857 10,857 Direct
2026-08-07 13,290 13,290 Direct
2025-08-08 9,786 9,786 Direct
2025-08-08 7,339 7,339 Direct
2024-08-09 12,670 12,670 Direct
2024-08-09 9,503 9,503 Direct
2023-08-18 14,476 14,476 Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.6400 to $271.5000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.8500 to $272.8300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.8500 to $273.7900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.3100 to $275.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.4000 to $276.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.6500 to $277.6200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.7700 to $278.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. Vests 2,500 share(s) on 07-Aug-2016, 2,500 share(s) on 07-Aug-2017, 2,500 share(s) on 07-Aug-2018, 1,579 share(s) on 07-Aug-2019
  10. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  11. Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  12. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)
  13. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  14. Fully exercisable
  15. Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
  16. Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
  17. Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.
  18. Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020.
Insider Monkey Quarterly Strategy
+334.6% Insider Monkey Quarterly Strategy
+149.4% Benchmark50% S&P 500 ETF and 50% Russell 2000 ETF
300%
200%
100%
Subscribe Now

Returns since its inception in May 2014 (through November 14th, 2024)